G
Gilead Sciences, Inc.
+ HoldingCYPH
+13.94%
3M Return
$1.710
-0.163 (-9.52%)Al cierre
Loading chart…
- High
- 1.840
- Open
- 1.820
- VWAP
- 1.72
- Vol
- 8.09M
- Mkt Cap
- —
- Low
- 1.620
- Amount
- 13.95M
- EV/EBITDA, TTM
- 0.00
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
AI analysis of Cypherpunk Technologies Inc (CYPH)
buyCypherpunk Technologies Inc is a good buy right now, primarily due to its recent price increase of 20.42% over the last five days and a significant 189.54% increase over the last 20 days. Additionally, the RSI is currently at 72.781, indicating strong momentum. However, the company reported a net income loss of $77,166,000 in Q1 2026, which poses a risk to its financial stability.
Métricas de valoración
The current forward P/E ratio for Cypherpunk Technologies Inc (CYPH) is 0.00, compared to its 5-year average forward P/E of -1.88.
Whales holding CYPH
Cronología de eventos
Noticias
8.508-18PRnewswireCypherpunk Launches World's Largest Zcash Mining Fleet
8.508-18NewsfilterCypherpunk Launches World's Largest Zcash Mining Fleet
9.008-12PRnewswireLeap Therapeutics Publishes Phase 2 Study Results on Sirexatamab for Colorectal Cancer
9.508-12PRnewswireCypherpunk Technologies Reports Significant Q2 Financial Improvement
6.007-01seekingalphaCantor Initiates Coverage of FWDI and CYPH with Overweight Rating
CYPH FAQ — answered by Alphio AI
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. It operates in the Healthcare sector.
Cypherpunk Technologies Inc is a good buy right now, primarily due to its recent price increase of 20.42% over the last five days and a significant 189.54% increase over the last 20 days. Additionally, the RSI is currently at 72.781, indicating strong momentum. However, the company reported a net income loss of $77,166,000 in Q1 2026, which poses a risk to its financial stability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.